Health Canada license renewal expands Numinus’ extensive list of permissible R&D activities VANCOUVER, BC, March 9, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received approval from Health Canada to…


Previous articlePT299 – Ed Prideaux – HPPD (Hallucinogen Persisting Perception Disorder): A Synopsis
Next articleSmall Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets